4.4 Article

Papillary urothelial neoplasm of Low malignant potential of the urinary bladder: clinicopathologic and outcome analysis from a single academic center

Journal

HUMAN PATHOLOGY
Volume 42, Issue 11, Pages 1799-1803

Publisher

W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.humpath.2011.03.006

Keywords

Papillary urothelial neoplasm of low malignant potential; PUNLMP; Noninvasive urothelial carcinoma; Recurrence rate; Progression rate; Prognosis

Categories

Funding

  1. Brady Urological Institute
  2. Flight Attendant Medical Research Institute

Ask authors/readers for more resources

Few long-term single-center studies have addressed the outcome of patients with papillary urothelial neoplasms of low malignant potential. Our study evaluates the behavior of these tumors occurring as primary urinary bladder lesions. For this purpose, 34 primary in-house cases diagnosed and treated between 1998 and 2008 were identified from our medical records. Upon review, 3 cases were upgraded to noninvasive low-grade urothelial carcinomas and excluded from further evaluation. During follow-up (range, 3-108 months; mean, 42 months), 13 patients developed recurrences; and 9 patients progressed to a noninvasive higher grade lesion (8 to low-grade and 1 to high-grade urothelial carcinomas). None of our patients developed stage progression (>pTa) or died of bladder cancer. Size of the primary tumor was associated with the risk of recurrence (P = .043), whereas the number of episodes of recurrence was associated with the likelihood of grade progression (P = .034). In conclusion, recurrences were observed in 42% of all our patients, with a grade progression rate of 29%. None of our patients developed invasive carcinoma or died as a consequence of their disease. Considering the low but definitive risk of recurrence and grade progression, appropriate clinical follow-up of patients with primary papillary urothelial neoplasm of low malignant potential is warranted. (C) 2011 Elsevier Inc. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Pathology

Spindle Cell Sarcoma of the Uterus Harboring MEIS1::NCOA1 Fusion Gene and Mimicking Endometrial Stromal Sarcoma

Haider A. Mejbel, Shuko Harada, Todd M. Stevens, Xiao Huang, George J. Netto, Alexander C. Mackinnon, Sameer Al Diffalha

Summary: MEIS1::NCOA1/2 sarcomas are rare low-grade tumors that often affect the genitourinary and gynecologic tracts. They can be diagnostically challenging due to their similarity to other entities, but molecular pathology plays a crucial role in arriving at an accurate diagnosis.

INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY (2023)

Article Medical Laboratory Technology

Urine Cytology Findings in Cases of Pseudocarcinomatous Urothelial Hyperplasia of the Bladder Often Represent a Diagnostic Challenge

Jaylou M. Velez Torres, Manuel Lora Gonzalez, Ernesto Martinez Duarte, Bassel Zein-Sabatto, Manju Aron, Nilesh S. Gupta, Darcy A. Kerr, George J. Netto, Merce Jorda, Oleksandr N. Kryvenko

Summary: In this study, the features of pseudocarcinomatous urothelial hyperplasia (PCUH) in urine cytology were described. The results showed that PCUH features in urine cytology can overlap with nonurothelial malignancies and lead to misdiagnosis initially.

ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2023)

Editorial Material Urology & Nephrology

Prostate Adenocarcinoma Grade Group 1: Rationale for Retaining a Cancer Label in the 2022 World Health Organization Classification

George J. Netto, Mahul B. Amin, Eva M. Comperat, Anthony J. Gill, Arndt Hartmann, Holger Moch, Santosh Menon, Maria R. Raspollini, Mark A. Rubin, John R. Srigley, Puay Hoon Tan, Satish K. Tickoo, Toyonori Tsuzuki, Samra Turajlic, Ian Cree, Daniel M. Berney

EUROPEAN UROLOGY (2023)

Letter Urology & Nephrology

Reply to Yongbao Wei, Haijian Huang, and Liefu Ye's Letter to the Editor re: George J. Netto, Mahul B. Amin, Daniel M. Berney, et al. The 2022 World Health Organization Classification of Tumors of the Urinary System and Male Genital Organs-Part B: Prostate and Urinary Tract Tumors. Eur Urol. 2022;82:469-82

Mark A. Rubin, Mahul B. Amin, Eva Comperat, Anthony Gill, Arndt Hartman, Santosh Menon, Maria Raspollini, John Srigley, Puay Hoon Tan, Satish Ticktoo, Toyonori Tsuzuki, Samra Turajlic, Ian Cree, Daniel Berney, Holger Moch, George J. Netto

EUROPEAN UROLOGY (2023)

Article Pathology

Clinical Significance of Perineural Invasion by Prostate Cancer Detected on Needle Core Biopsy Unilateral vs Bilateral Involvement

Yuki Teramoto, Numbereye Numbere, Ying Wang, Hiroshi Miyamoto

Summary: The laterality of perineural invasion (PNI) in prostate cancer has a significant impact on clinical outcomes. Patients with bilateral PNI have a higher risk of disease progression after radical prostatectomy (RP) compared to those with unilateral PNI.

AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2023)

Review Oncology

Recent advances in the understanding of urothelial tumorigenesis

Masato Yasui, Liam Cui, Hiroshi Miyamoto

Summary: Patients with non-muscle-invasive bladder tumor often experience recurrence even after surgery, and muscle-invasive disease is often fatal. It is crucial to understand the molecular mechanisms responsible for bladder tumor progression and tumorigenesis.

EXPERT REVIEW OF ANTICANCER THERAPY (2023)

Article Pathology

Comedonecrosis within conventional prostatic adenocarcinoma vs. intraductal carcinoma of the prostate: their clinical significance is not comparable*

Ying Wang, Yuki Teramoto, Hiroshi Miyamoto

Summary: It is controversial whether Gleason grade should be assigned to intraductal carcinoma of the prostate (IDC-P) and if the prognostic value of comedonecrosis associated with IDC-P is equivalent to that in conventional/invasive prostatic adenocarcinoma (CPA) as a Gleason grade 5 pattern. This study evaluated radical prostatectomy findings and postoperative outcomes in 287 patients with CPA exhibiting any Gleason pattern 5. The presence of necrosis only in IDC-P was found to be associated with significantly worse oncologic outcomes, compared with necrosis only in CPA, suggesting that IDC-P necrosis should not be simply considered as a grade 5 pattern.

HUMAN PATHOLOGY (2023)

Article Oncology

The impact of routine frozen section analysis during nephroureterectomy or segmental ureterectomy for urothelial carcinoma on final surgical margin status and long-term oncologic outcome

Wilrama Lima, Ying Wang, Hiroshi Miyamoto

Summary: This study evaluated the clinical significance of intraoperative frozen section analysis (FSA) in patients with upper urinary tract cancer. The results showed that FSA can significantly reduce the risk of positive surgical margins in patients with ureteral tumors, but routine FSA for upper urinary tract cancer did not improve long-term oncologic outcomes significantly.

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2023)

Article Urology & Nephrology

Risk Stratification by Quantification of Perineural Cancer Invasion on Prostate Needle Core Biopsy: Should It Be Counted?

Yuki Teramoto, Ying Wang, Hiroshi Miyamoto

Summary: Quantification of perineural invasion on prostate biopsy showed significance as an independent predictor of prognosis, with multifocal perineural invasion and >1 perineural invasion per 10-mm tumor associated with worse outcomes after radical prostatectomy. Additionally, assigning points for multifocal perineural invasion improved the accuracy of predicting 5-year recurrence-free survival.

JOURNAL OF UROLOGY (2023)

Review Chemistry, Medicinal

Profile of Relugolix in the Management of Advanced Hormone-Sensitive Prostate Cancer: Design, Development, and Place in Therapy

Tomoyuki Tatenuma, Hiroshi Miyamoto

Summary: Androgen deprivation therapy is the main treatment for advanced prostate cancer, and relugolix has been developed as an oral alternative. Previous studies have shown comparable efficacy between relugolix and other gonadotropin-releasing hormone antagonists or agonists. This review summarizes the design, development, and therapeutic application of relugolix and discusses its potential as a promising oral alternative to injectable therapy.

DRUG DESIGN DEVELOPMENT AND THERAPY (2023)

Article Oncology

An international multi-institutional validation study of the algorithm for prostate cancer detection and Gleason grading

Yuri Tolkach, Vlado Ovtcharov, Alexey Pryalukhin, Marie-Lisa Eich, Nadine Therese Gaisa, Martin Braun, Abdukhamid Radzhabov, Alexander Quaas, Peter Hammerer, Ansgar Dellmann, Wolfgang Hulla, Michael C. Haffner, Henning Reis, Ibrahim Fahoum, Iryna Samarska, Artem Borbat, Hoa Pham, Axel Heidenreich, Sebastian Klein, George Netto, Peter Caie, Reinhard Buettner

Summary: This retrospective study validates a deep learning-based classifier for prostate cancer (PCA) detection and Gleason grading (AI tool) in biopsy samples. The AI tool showed high accuracy in tumor detection and had similar accuracy in Gleason grading compared to experienced pathologists.

NPJ PRECISION ONCOLOGY (2023)

Review Pathology

News in the classification of WHO 2022 bladder tumors

Maria Rosaria Raspollini, Eva M. Comperat, Antonio Lopez-Beltran, Rodolfo Montironi, Alessia Cimadamore, Toyonori Tsuzuki, George J. Netto

Summary: The fifth edition of WHO Classification of Tumors series for urinary and male genital tract tumors has been published after six years of the fourth edition. New treatment approaches and molecular data on urological cancers have been implemented during these years. Although morphology remains the basis for taxonomy, a molecular approach and new therapeutic modalities like immunotherapy are emerging. More data is required for the application of these advances in routine pathology practice and patient management.

PATHOLOGICA (2023)

Article Pathology

Nested and Large Nested Subtypes of Urothelial Carcinoma of the Upper Urinary Tract: A Multi-institutional Study

Manju Arona, Darshan S. Chandrashekarc, Sofia Canete-Portilloc, Fadi Brimod, Sean R. Williamsone, Adeboye O. Osunkoyaf, Maria Rosaria Raspollinih, Lakshmi P. Kunjui, Sooryanarayana Varamballyc, Alexander C. Mackinnonc, Shuko Haradac, George J. Nettoc

Summary: Nested urothelial carcinoma (NUC) and large nested urothelial carcinoma (LNUC) of the upper urinary tract are rare tumors. This study provides insights into their clinicopathological and molecular characteristics, revealing better clinical outcomes for LNUC and a higher prevalence of pathogenic mutations in FGFR3 and PIK3CA in LNUC.

MODERN PATHOLOGY (2023)

No Data Available